看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -0.1x - -0.1x | -0.1x |
| Historical Pb Multiple | -3.6x - 10.7x | -0.1x |
| Fair Value | $0.0054 - $0.0060 | $0.0057 |
| Upside | -43.1% - -37.1% | -40.1% |
| Benchmarks | - | Full Ticker |
| Harrow, Inc. | - | NasdaqGM:HROW |
| Elanco Animal Health Incorporated | - | NYSE:ELAN |
| Clearside Biomedical, Inc. | - | NasdaqGM:CLSD |
| Petros Pharmaceuticals, Inc. | - | NasdaqCM:PTPI |
| Kaya Holdings, Inc. | - | OTCPK:KAYS |
| CNBX Pharmaceuticals Inc. | - | OTCPK:CNBX |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| HROW | ELAN | CLSD | PTPI | KAYS | CNBX | |||
| NasdaqGM:HROW | NYSE:ELAN | NasdaqGM:CLSD | NasdaqCM:PTPI | OTCPK:KAYS | OTCPK:CNBX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 37.8% | NM- | NM- | -19.5% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 28.4% | 127.5% | -5.7% | -94.0% | -191.2% | 84.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -17.7% | -10.2% | -819.4% | -230.9% | -187.0% | -39822.4% | ||
| Prior Fiscal Year | -18.7% | -27.9% | -394.9% | -237.3% | -521.8% | -904.6% | ||
| Latest Fiscal Year | -8.8% | 7.6% | -2064.4% | -524.2% | 820.0% | -534.5% | ||
| Latest Twelve Months | -8.8% | 7.6% | -2064.4% | -524.2% | -4463.2% | -1356.0% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -70.8% | -6.2% | -320.6% | -140.6% | NA | -244.7% | ||
| Prior Fiscal Year | -49.6% | -18.2% | -612.5% | -96.0% | NM | NM | ||
| Latest Twelve Months | -24.9% | 5.5% | NM | -444.0% | NM | NM | ||
| Next Fiscal Year | 37.4% | 6.5% | 65.3% | 91.7% | #NUM! | #NUM! | ||
| Two Fiscal Years Forward | 60.6% | 7.2% | 62.3% | 48.4% | -12.4% | 24.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 4.4x | 1.0x | 35.5x | 0.5x | 25.0x | 5.8x | ||
| Price / LTM EPS | -49.8x | 12.6x | -1.7x | -0.1x | -0.6x | -0.4x | ||
| Price / Book | 12.5x | 0.7x | -1.5x | -0.3x | -0.1x | -0.1x | ||
| Price / Fwd Book | 8.8x | 0.7x | -0.8x | -0.1x | -0.1x | -0.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -1.5x | -0.1x | 12.5x | |||||
| Historical P/B Ratio | -3.6x | -0.1x | 10.7x | |||||
| Selected P/B Multiple | -0.1x | -0.1x | -0.1x | |||||
| (x) Book Value | (3) | (3) | (3) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | HROW | ELAN | CLSD | PTPI | KAYS | CNBX | |
| Value of Common Equity | 870 | 4,293 | 62 | 2 | 2 | 0 | |
| (/) Shares Outstanding | 35.7 | 494.6 | 77.1 | 53.5 | 41.6 | 33.9 | |
| Implied Stock Price | 24.40 | 8.68 | 0.80 | 0.05 | 0.04 | 0.01 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 24.40 | 8.68 | 0.80 | 0.05 | 0.04 | 0.01 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |